ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Philips extends company’s mobile C-arm portfolio with Zenition 10

May 2, 2023

  • New cost-effective addition to Philips Image Guided Therapy Mobile C-arm platform brings flat panel imaging and ease-of-use to routine surgery
  • Unique user profiles, application-specific protocols and high range of movement enhance the operating room staff experience and contribute to improved patient outcomes

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Image Guided Therapy Mobile C-arm System 1000 – Zenition 10, a new addition to the company’s Zenition mobile C-arm series. Based on Philips’ state-of-the-art flat panel detector technology, Zenition 10 helps to expand patient access to routine surgical care and minimally invasive procedures. Now commercially available [1], the cost-effective, high-utilization, high-image-quality mobile C-arm enables surgeons to treat more patients at a lower cost while helping improve patient outcomes.

“Philips Zenition mobile C-arms have long been recognized for their high-quality imaging and efficiency-enhancing performance. With the introduction of Zenition 10, we are making those benefits available on a C-arm that meets the wide-ranging needs of routine open and minimally invasive surgery, allowing more patients in more parts of the world to receive the high-quality care,” said Mark Stoffels, General Manager, Image Guided Therapy Systems at Philips.

Mitigating staff shortages, increasing access to high-quality care
To help alleviate operating room staff shortages and rising healthcare costs, Philips Zenition 10 provides a cost-effective imaging solution for routine surgery, delivers the speed and efficiency needed to deal with high patient throughput, while being flexible enough to meet the needs of orthopedics, trauma, and other areas of surgery to maximize utilization. It comes with exceptional C-arm maneuverability, application-specific protocols, and personalized user profiles. At the same time, it delivers the excellent image quality needed to improve patient outcomes. User-friendly and intuitive to operate, the Zenition 10 supports a fast learning curve and reduces operating staff training time. Next to this, the new system offers a dedicated low-dose pediatric mode.

Consistent image quality is facilitated by application-specific protocols, customizable presets, and unique user profiles that automatically adjust Zenition 10 settings to suit an individual user’s preferences whenever they log in. An uninterruptible power supply allows the unit to be moved from one operating room to another without the need to reboot the entire system. Its excellent C-arm geometry provides the maneuverability needed for operating room staff to access target anatomies. Philips BodySmart facilitates dose efficiency by automatically
adapting the measuring field to the area of interest.

For images of patients with metal implants, Philips MetalSmart software automatically enhances image quality and dose efficiency. A dedicated pediatric mode automatically reduces dose rates for young patients. The system's digital subtraction angiography capability further enhances the range of surgical procedures facilitated by the Zenition 10, allowing clear imaging of vasculatures.

The Zenition mobile C-arm platform brings together innovations in image capture, image processing, ease-of-use, and versatility pioneered on Philips’ highly successful and Windows® based Zenition platform. Other C-arm systems in Philips’ Zenition series are the Zenition 50 and Zenition 70.

[1] Zenition 10 mobile C-arm systems are available for sale in a limited number of countries. Please check with a local representative for availability in your market.


For further information, please contact:

Joost Maltha 
Philips Global Press Office 
Tel: +31 6 10 55 8116  
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.25
+2.28 (1.00%)
AAPL  269.00
+0.19 (0.07%)
AMD  258.01
-1.66 (-0.64%)
BAC  52.87
-0.15 (-0.28%)
GOOG  268.43
-1.50 (-0.56%)
META  751.44
+0.62 (0.08%)
MSFT  542.07
+10.55 (1.98%)
NVDA  201.03
+9.54 (4.98%)
ORCL  280.83
-0.57 (-0.20%)
TSLA  460.55
+8.13 (1.80%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.